A share price of Xeris Biopharma Holdings Inc [XERS] is currently trading at $7.01, up 0.29%. An important factor to consider is whether the stock is rising or falling in short-term value. The XERS shares have gain 8.35% over the last week, with a monthly amount drifted -5.65%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xeris Biopharma Holdings Inc [NASDAQ: XERS] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $9. On November 11, 2024, downgrade downgraded it’s rating to Neutral but maintained its price target of $3 on the stock. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $5 on March 28, 2024. Craig Hallum initiated its recommendation with a Buy and recommended $4.50 as its price target on August 28, 2023. Jefferies started tracking with a Buy rating for this stock on October 21, 2022, and assigned it a price target of $4. In a note dated April 28, 2022, Craig Hallum initiated a Buy rating and provided a target price of $6.50 on this stock.
Xeris Biopharma Holdings Inc experienced fluctuations in its stock price throughout the past year between $3.14 and $10.08. Currently, Wall Street analysts expect the stock to reach $13.5 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $7.01 at the most recent close of the market. An investor can expect a potential return of 92.58% based on the average XERS price forecast.
Analyzing the XERS fundamentals
Trailing Twelve Months sales for Xeris Biopharma Holdings Inc [NASDAQ:XERS] were 266.14M which represents 37.06% growth. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.04%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is 1.14 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -13.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.87 points at the first support level, and at 6.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.22, and for the 2nd resistance point, it is at 7.44.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Xeris Biopharma Holdings Inc [NASDAQ:XERS] is 1.93. On the other hand, the Quick Ratio is 1.35, and the Cash Ratio is 0.62. Considering the valuation of this stock, the price to sales ratio is 4.37.
Transactions by insiders
Recent insider trading involved Hecht Beth, that happened on Dec 01 ’25 when 16667.0 shares were sold. Shannon John Patrick Jr completed a deal on Nov 13 ’25 to sell 23242.0 shares. Meanwhile, Hecht Beth sold 16667.0 shares on Nov 11 ’25.
